论文部分内容阅读
目的探讨罗格列酮对急性冠脉综合征(ACS)患者冠脉介入术(PCI)预后的影响。方法将60例行PCI治疗的ACS患者分为2组,罗格列酮治疗组及对照组各30例,治疗组在常规治疗的基础上应用罗格列酮4 mg/d治疗半年,观察PCI术后2组患者心绞痛发作情况及EF值的变化,并检测治疗前后血浆内皮素(ET)、一氧化氮(NO)、C反应蛋白(CRP)水平,做治疗后组间对比。结果治疗组心绞痛发生率明显下降,P<0.01,心机梗死发生率下降,P<0.05,EF值治疗组较对照组明显改善P<0.01,治疗组治疗后NO明显升高,而ET、CRP明显下降,与对照组比较P<0.01,两组差异有统计学意义。结论罗格列酮可减少ACS患者PCI术后不良心血管事件的发生率。
Objective To investigate the effect of rosiglitazone on the prognosis of patients with acute coronary syndrome (ACS) undergoing coronary intervention. Methods Sixty ACS patients undergoing PCI were divided into two groups: 30 patients in the rosiglitazone group and 30 patients in the control group. The patients in the treatment group were treated with rosiglitazone 4 mg / d for 6 months on the basis of routine treatment. The postoperative angina pectoris and changes of EF value were measured before and after treatment. The levels of plasma ET, NO and CRP were measured before and after treatment. Results The incidence of angina in treatment group decreased significantly (P <0.01), the incidence of cardiocardial infarction decreased (P <0.05), and the value of EF in treatment group was significantly improved than that in control group (P <0.01) Decreased, compared with the control group P <0.01, the difference between the two groups was statistically significant. Conclusion Rosiglitazone can reduce the incidence of adverse cardiovascular events after PCI in ACS patients.